Neisseria gonorrhoeae Monoclonal Antibody (6144), Invitrogen™

Description

• Specificity: Reactive with all strains of N
• gonorrhoeae tested
• Reactive with: 9 strains of N
• gonorrhoeae, N
• lactamica & N
• meningitidis
• Non-reactive with: N
• mucosa, N
• perflava, N
• sicca, Gardnerella vaginalis, group B Streptococcus, Candida albicans, Hemophilus influenza type B, Chlamydia trachomatis, Trichomonas vaginalis, Mycoplasma genitalium, Ureaplasma urealyticum & Herpes simplex virus type 2
• Purified preparations consist of >90% pure mouse monoclonal antibody which has been purified from ascites fluid by protein A chromatography
• The final preparation is formulated to a protein concentration of 100 μg/mL in 0.01 M phosphate buffered saline, pH 7.2 and contains 0.1% sodium azide
• Each vial contains 1.0 mL
• This product contains no stabilizing proteins and should be stored at 4C until ready for use
• Working dilution must be determined by the user
• Suggested starting ranges are 1:10-1:50 for ICC/IF and 1:20-1:200
• for ELISA
• Although pathogenic bacteria constitute only a small portion of bacterial species, infectious diseases caused by pathogenic bacteria affect millions of people worldwide
• Diarrheal diseases, many of which are bacterial, are the second leading cause of death worldwide, claiming an estimated 5 million people annually
• Furthermore, an estimated 3 million people die of tuberculosis annually, 500,000 people die of pertussis, and 25,000 die of typhoid
• The ability of bacteria to utilize various food sources is a major factor behind their pervasiveness
• Their vast numbers lead to rapid evolutionary changes resulting in emerging diseases as well as antibiotic-resistant strains of well known diseases
• Examples of these are multi-drug resistant tuberculosis and methicillin-resistant Staphylococcus aureus
• Research into the detection and treatment of these infectious disease agents will continue to expand in an effort to alleviate the effects of these diseases.